| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Abnormality v jednom ze dvou kooperujících genů, p53 nebo ATM, znamenají pro pacienty s B-CLL velmi špatnou prognózu. Tyto abnormality byly již v dřívějších studiích asociovány s nemutovaným subtypem IgVH a mohou tak teoreticky odrážet jeho agresivnější chování. Avšak jedna recentní práce (Sturm et al., Cell Death Differ 2003, 10: 477 to 484) zaznamenala jasnou korelaci mezi inaktivací p53 a předchozí DNA-poškozující léčbou, zahrnující alkylační látky. Provedli jsme podrobnou analýzu statutu genu p53 u 168 B-CLL pacientů (včetně funkční analýzy FASAY) a skrínink delecí v lokusu ATM u 69% těchto vzorků a korelovali jsme data k mutačnímu stavu IgVH a předchozí léčbě. Inaktivace p53 (celková frekvence 12%) se vyskytovala významně častěji (P<0.05) a dalece ATM (celková frekvence 18%) striktně (P<0.001) u nemutovaného subtypu IgVH. Statisticky významná korelace nebyla zjištěna mezi přítomností předchozí léčby (zahrnující alkylační látky ve 44/49 případů) a abnormalitami v genech p53 nebo ATM. (cs)
- Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P<0.05) and deletions of ATM (overall frequency 18%) strictly (P<0.001) in the unmutated IgVH subtype.
- Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P<0.05) and deletions of ATM (overall frequency 18%) strictly (P<0.001) in the unmutated IgVH subtype. (en)
|
| Title
| - Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment
- Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment (en)
- Inaktivace p53 a delece ATM u B-CLL pacientů ve vztahu k mutačnímu stavu IgVH a předchozí léčbě (cs)
|
| skos:prefLabel
| - Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment
- Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment (en)
- Inaktivace p53 a delece ATM u B-CLL pacientů ve vztahu k mutačnímu stavu IgVH a předchozí léčbě (cs)
|
| skos:notation
| - RIV/65269705:_____/06:#0000047!RIV08-MZ0-65269705
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(NR8068), P(NR8443), P(NR8445), P(NR8448)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/65269705:_____/06:#0000047
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - B-CLL; FASAY; IgVH; p53; ATM; previous treatment (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Brychtová, Yvona
- Dvořáková, Dana
- Mayer, Jiří
- Pospíšilová, Šárka
- Vorlíček, Jiří
- Malčíková, Jitka
- Trbušek, Martin
- Šmardová, Jana
- Doubek, Michal
|
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)